Orchid Pharma's 4,45,86,052 amalgamation shares begin trading
As filed · Orchid Pharma Limited has informed the Exchange regarding 'Trading Approval of Equity Shares issued and allotted under Scheme of Amalgamation'.
What happened
FactOrchid Pharma said 4,45,86,052 equity shares allotted under its NCLT-sanctioned scheme of amalgamation were listed and admitted to trading on NSE and BSE from September 23, 2026.
Why it matters
CapitSignal interpretationA merger fixes a share-exchange ratio, which permanently sets how much of the combined company existing holders own.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
DelayedWe'll probably have the exact number, say, after a few months' time.
as our cefiderocol project will get started, say, in the next year, then we will take validation batches and hopefully, after two years, we would be able to -- once we are able to register the product from our side, we would be able to supply some percentage from our side.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Swap ratio and its valuation basis
- Regulatory and NCLT approvals required
- Appointed date
- Hopefully, within this quarter, we should announce one. (management committed by Q4 FY26)
- The first sales actually would be to Orchid itself internally. (management committed by Q1 FY27)
Evidence
- Orchid Pharma Limited has informed the Exchange regarding 'Trading Approval of Equity Shares issued and allotted under Scheme of Amalgamation'.(opens the original filing in a new tab)
- Earlier statement · FY26
- Latest statement · FY27
- Earlier statement · FY27
How CapitSignal classified this
- Reasoning:
- The admission of these scheme-related shares to trading completes a key implementation step of the amalgamation and makes the newly allotted shares tradable.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%